Cargando…

Efficacy of Nebulized Glycopyrrolate on Lung Hyperinflation in Patients with COPD

INTRODUCTION: Lung hyperinflation in chronic obstructive pulmonary disease (COPD) is associated with activity limitation, impaired cardiac output, and mortality. Several studies have demonstrated that long-acting muscarinic antagonists (LAMAs) delivered by dry powder inhalers can promote lung deflat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Siler, Thomas M., Hohenwarter, Claire, Xiong, Kuangnan, Sciarappa, Kenneth, Sanjar, Shahin, Sharma, Sanjay
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8260570/ https://www.ncbi.nlm.nih.gov/pubmed/34232493 http://dx.doi.org/10.1007/s41030-021-00166-5

Ejemplares similares

Impact of baseline clinical features on outcomes of nebulized glycopyrrolate therapy in COPD
por: Tashkin, Donald P., et al.
Publicado: (2021)

Impact of Comorbidity Prevalence and Cardiovascular Disease Status on the Efficacy and Safety of Nebulized Glycopyrrolate in Patients with COPD
por: Putcha, Nirupama, et al.
Publicado: (2021)

Effect of Gender on Lung Function and Patient-Reported Outcomes in Patients with COPD Receiving Nebulized Glycopyrrolate
por: Ohar, Jill A, et al.
Publicado: (2020)

Effect of SGRQ-Defined Chronic Bronchitis at Baseline on Treatment Outcomes in Patients with COPD Receiving Nebulized Glycopyrrolate
por: Tashkin, Donald P, et al.
Publicado: (2021)

Improvement in Lung Function and Patient-Reported Outcomes in Patients with COPD with Comorbid Anxiety and Depression Receiving Nebulized Glycopyrrolate in the GOLDEN 3 and 4 Studies
por: Hanania, Nicola A, et al.
Publicado: (2021)

The Effect of Baseline Rescue Medication Use on Efficacy and Safety of Nebulized Glycopyrrolate Treatment in Patients with COPD from the GOLDEN 3 and 4 Studies
por: Donohue, James F, et al.
Publicado: (2020)

Efficacy and safety of a novel, nebulized glycopyrrolate for the treatment of COPD: effect of baseline disease severity and age; pooled analysis of GOLDEN 3 and GOLDEN 4
por: Ohar, Jill, et al.
Publicado: (2018)

Effect of background long-acting beta(2)-agonist therapy on the efficacy and safety of a novel, nebulized glycopyrrolate in subjects with moderate-to-very-severe COPD
por: Kerwin, Edward M, et al.
Publicado: (2018)

In Vitro Effect of Different Airflow Rates on the Aerosol Properties of Nebulized Glycopyrrolate in the eFlow® Closed System and Tiotropium Delivered in the HandiHaler®
por: Ohar, Jill A., et al.
Publicado: (2020)

Efficacy and safety of glycopyrrolate in patients with COPD by reversibility: pooled analysis of GEM1 and GEM2 12-week studies
por: Ohar, Jill A, et al.
Publicado: (2019)

Effect of Gender on Lung Function and Patient-Reported Outcomes in Patients with COPD Receiving Nebulized Glycopyrrolate [Corrigendum]
Publicado: (2021)

Effect of smoking status on lung function, patient-reported outcomes, and safety among COPD patients treated with glycopyrrolate inhalation powder: pooled analysis of GEM1 and GEM2 studies
por: Tashkin, Donald P., et al.
Publicado: (2019)

Efficacy and safety of nebulized glycopyrrolate for administration using a high efficiency nebulizer in patients with chronic obstructive pulmonary disease
por: Leaker, Brian R, et al.
Publicado: (2015)

Role of nebulized glycopyrrolate in the treatment of chronic obstructive pulmonary disease
por: Santus, Pierachille, et al.
Publicado: (2017)

Longitudinal changes in lung hyperinflation in COPD
por: Park, Jimyung, et al.
Publicado: (2017)

No room to breathe: the importance of lung hyperinflation in COPD
por: Thomas, Mike, et al.
Publicado: (2013)

The Effect of Baseline Rescue Medication Use on Efficacy and Safety of Nebulized Glycopyrrolate Treatment in Patients with COPD from the GOLDEN 3 and 4 Studies [Corrigendum]
Publicado: (2020)

In Vitro Characterization of the eFlow Closed System Nebulizer with Glycopyrrolate Inhalation Solution
por: Pham, Stephen, et al.
Publicado: (2018)

Cardiovascular effects of exercise induced dynamic hyperinflation in COPD patients—Dynamically hyperinflated and non-hyperinflated subgroups
por: Lukacsovits, Jozsef, et al.
Publicado: (2023)

Hyperinflation and its management in COPD
por: Puente-Maestu, Luis, et al.
Publicado: (2006)

The lungs need to be deflated: effects of glycopyrronium on lung hyperinflation in COPD patients
por: Sanguinetti, Claudio M
Publicado: (2014)

Dose selection for glycopyrrolate/eFlow(®) phase III clinical studies: results from GOLDEN (Glycopyrrolate for Obstructive Lung Disease via Electronic Nebulizer) phase II dose-finding studies
por: Donohue, James F., et al.
Publicado: (2017)

Resting hyperinflation and emphysema on the clinical course of COPD
por: Kim, Yeon Wook, et al.
Publicado: (2019)

Effects of beclomethasone/formoterol fixed combination on lung hyperinflation and dyspnea in COPD patients
por: Tzani, Panagiota, et al.
Publicado: (2011)

Chronotropic incompetence can limit exercise tolerance in COPD patients with lung hyperinflation
por: Hulo, Sébastien, et al.
Publicado: (2016)

Efficacy of Glycopyrrolate in Primary Hyperhidrosis Patients
por: Lee, Hyun Ho, et al.
Publicado: (2012)

Early COPD patients with lung hyperinflation associated with poorer lung function but better bronchodilator responsiveness
por: Chen, Chunlan, et al.
Publicado: (2016)

Effects of airway obstruction and hyperinflation on electrocardiographic axes in COPD
por: Alter, Peter, et al.
Publicado: (2019)

Inspiratory drive is related to dynamic pulmonary hyperinflation in COPD patients
por: Gatta, Diego, et al.
Publicado: (2013)

Effects of inspiratory muscle training on dynamic hyperinflation in patients with COPD
por: Petrovic, Milos, et al.
Publicado: (2012)

Diaphragm dome height on chest radiography as a predictor of dynamic lung hyperinflation in COPD
por: Shiraishi, Masashi, et al.
Publicado: (2023)

The Impact of Homogeneous Versus Heterogeneous Emphysema on Dynamic Hyperinflation in Patients With Severe COPD Assessed for Lung Volume Reduction
por: Boutou, Afroditi K., et al.
Publicado: (2015)

Lung hyperinflation and functional exercise capacity in patients with COPD – a three-year longitudinal study
por: Aalstad, Linn T., et al.
Publicado: (2018)

Efficacy of tiotropium and indacaterol monotherapy and their combination on dynamic lung hyperinflation in COPD: a random open-label crossover study
por: Fujimoto, Keisaku, et al.
Publicado: (2017)

Effect of obesity on constant workrate exercise in hyperinflated men with COPD
por: Laviolette, Louis, et al.
Publicado: (2010)

Influence of body mass on predicted values of static hyperinflation in COPD
por: Alter, Peter, et al.
Publicado: (2018)

Bronchodilators for hyperinflation in COPD associated with biomass smoke: clinical trial
por: Ramírez-Venegas, Alejandra, et al.
Publicado: (2019)

Functional respiratory imaging assessment of budesonide/glycopyrrolate/formoterol fumarate and glycopyrrolate/formoterol fumarate metered dose inhalers in patients with COPD: the value of inhaled corticosteroids
por: van den Berge, Maarten, et al.
Publicado: (2021)

Diaphragmatic excursion correlates with exercise capacity and dynamic hyperinflation in COPD patients
por: Shiraishi, Masashi, et al.
Publicado: (2020)

Nebulized formoterol: a review of clinical efficacy and safety in COPD
por: Gross, Nicholas J, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_185e9dq4lsbpjq2c0h04leeti9